The U.S. trade deficit jumped to a 30-month high in September, keeping the economy from posting a second straight 3% increase ...
Much has been made of the elevated readings on the Cboe Volatility Index over the past month or so. But how does Wall ...
A Kamala Harris presidency or Donald Trump in the White House would mean divergent things for Americans' wallets, as the two candidates differ greatly on issues including taxes and housing. Here is a ...
Shares of avocado-producer Mission Produce popped Tuesday after the company said it expected an increase in revenue and adjusted profits in the fiscal fourth quarter. The stock was up 9.1% to $13.23 ...
The bottom line included $48 million in charges tied to Trulieve supporting Amendment 3 in Florida, which would legalize cannabis for recreational use in the state. Excluding those charges, the ...
Yum Brands Inc.’s stock fell 1.5% early Tuesday, after the operator of Pizza Hut, Taco Bell and KFC restaurants third-quarter earnings fell short of estimates, weighted down by conflicts around the ...
Portillo's posted a drop in comparable restaurant sales in the third quarter as the number of transactions fell, despite a boost from higher prices. The Oak Brook, Ill.-based fast-casual restaurant ...
Shares of Trump-related mobile-advertising company Phunware Inc. are up 7.1% on election day, continuing their recent rally. The stock ended Monday's session up 2.5% to snap a five-day losing streak.
On Monday, Engine Capital, which owns about 7.1% of the Canadian cloud-based software and technology company, proposed six new candidates to replace the current board, including Arnaud Ajdler, the ...
Merus on Tuesday said the Food and Drug Administration extended its review of the clinical-stage oncology company's proposed zenocutuzumab cancer treatment.
Cummins said third-quarter sales rose slightly and came in better than Wall Street predicted, as they were boosted in part by gains in two of its segments on data center-related demand. The ...
Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...